Literature DB >> 32424692

Treatment Goals in Psoriasis: Which Outcomes Matter Most?

Steven A Svoboda1, Rima I Ghamrawi2, Dorellie A Owusu2, Steven R Feldman2,3,4,5.   

Abstract

Psoriasis is a chronic immune-mediated inflammatory disease that predominantly affects the skin and joints. Its detrimental effects on the physical, psychosocial, and emotional well-being of patients leads to a significant reduction in quality of life (QoL). The goals of treatment focus on decreasing disease severity and improving QoL for patients; accomplishing these goals requires physicians to understand both the full impact of the disease on a patient's life and the outcomes that matter most to patients. The use of outcome measures, both physician- and patient-reported, can assist clinicians in evaluating the disease burden and its effect on QoL and in identifying patient preferences for treatment, ultimately enhancing quality of care. However, current outcome measures have many limitations and do not adequately capture patients' needs and priorities. Nevertheless, physicians treating patients with psoriasis are encouraged to utilize these instruments while remaining cognizant of each of their limitations. As there is no consensus on an outcome measure that fully encompasses the complexities of psoriasis and its impact on patients, instruments that are appropriate and applicable to dermatologists and their patients should be developed.

Entities:  

Mesh:

Year:  2020        PMID: 32424692     DOI: 10.1007/s40257-020-00521-3

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  5 in total

1.  The Use of Metrics in Daily Practice and the Perception of Psoriasis-Associated Comorbidities: Discrepancies Between Research and Real-World.

Authors:  Tom Hillary; Jo Lambert
Journal:  Psoriasis (Auckl)       Date:  2021-12-21

2.  Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians.

Authors:  I van Ee; E Deprez; A Egeberg; M Augustin; C Conrad; V Corazza; L Donati; J Lambert; R Lăpădatu; A Meyer; C Paul; R Penzer-Hick; K Stephen; J van der Zon; A Bewley
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-12-27       Impact factor: 9.228

3.  Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.

Authors:  A Jalili; P Calzavara-Pinton; L Kircik; D Lons-Danic; A Pink; S Tyring; P de la Cueva; M Gooderham; S Segaert; N Nyholm; H Thoning; B Petersen; D Thaçi
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-10-21       Impact factor: 9.228

4.  Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews.

Authors:  Jie Zhang; Qianying Yu; Li Peng; Yuesi Qin; Mingyi Jing; Dan Huang; Jing Guo; Min Xiao; Mingling Chen
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

5.  Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.

Authors:  Kim A Papp; Ahmed M Soliman; Nicolae Done; Christopher Carley; Esteban Lemus Wirtz; Luis Puig
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.